title: Drug-induced parkinsonism: cinnarizine and flunarizine are potent uncouplers of the vacuolar H+-ATPase in catecholamine storage vesicles.
abstract: Cinnarizine (1-diphenylmethyl-4-(3-phenyl-2-propenyl)piperazine) and its di-fluorinated derivative flunarizine inhibit the MgATP-dependent generation of a transmembrane proton electrochemical gradient in chromaffin granule ghosts. The concentrations giving 50% inhibition (IC50) of the MgATP-dependent generation of the pH-gradient were 5.9+/-0.6 microM (n = 6) and 3.0+/-0.3 microM (n = 5) for cinnarizine and flunarizine, respectively. The IC50 values for inhibiting the generation of the membrane potential were even lower, i.e. 0.19+/-0.06 microM (n = 6) and 0.15+/-0.01 microM (n = 4) for cinnarizine and flunarizine, respectively. Cinnarizine (10 microM) also inhibited the energy-dependent vesicular uptake of [14C]-dopamine (50 microM) by 76%, i.e. from 2.1+/-0.9 to 0.5+/-0.6 nmol/mg protein/min (n = 5, P < 0.002). Cinnarizine (10 microM) increased the MgATPase activity of the granule ghosts by 47+/-26% (n = 4) compatible with an uncoupling of the vacuolar H+-ATPase activity. The IC50-values observed for the two compounds are in the same range as their reported therapeutic plasma concentrations in vivo, suggesting that cinnarizine and flunarizine may well inhibit proton pumping and catecholamine uptake in storage vesicles also in vivo. This mechanism of action may contribute to the drug-induced parkinsonism seen as a side-effect of the two drugs.
authors.affiliation: Department of Biochemistry and Molecular Biology, University of Bergen, Norway.
authors.forename: O
authors.initials: O
authors.lastname: Terland
authors.forename: T
authors.initials: T
authors.lastname: Flatmark
mesh_terms: D000818:Animals; D002417:Cattle; D019439:Chromaffin Cells / Q000187:drug effects / Q000378:metabolism; D002936:Cinnarizine / Q000633:toxicity*; D004298:Dopamine / Q000378:metabolism*; D004734:Energy Metabolism / Q000187:drug effects; D005444:Flunarizine / Q000633:toxicity*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced*; D006180:Proton-Translocating ATPases / Q000378:metabolism*; D013572:Synaptic Vesicles / Q000187:drug effects / Q000378:metabolism; D014475:Uncoupling Agents / Q000633:toxicity*; D014617:Vacuoles / Q000187:drug effects* / Q000201:enzymology
chemical_list: D014475:Uncoupling Agents; D002936:Cinnarizine; D006180:Proton-Translocating ATPases; D005444:Flunarizine; D004298:Dopamine